"Our study evaluated the skin toxicity and early cardiac toxicity of concurrent Trastuzumab and radiation therapy treatment in the adjuvant setting," says Penny Anderson, M.D., radiation ...

However, chemotherapy has always come with toxicity issues, a problem that scientists intend to tackle head-on. HER2+ breast cancer is a common subtype of breast cancer with a standard treatment of ...

The drug can cause pulmonary toxicity in the ... patients for reactions like skin rash, shortness of breath, nausea, dizziness, low blood pressure. Store Trastuzumab in the refrigerator at 2 ...

Trastuzumab duocarmazine (T-Duo ... growth factor receptor 2–positive (HER2+) breast cancer. However, ocular toxicity was prevalent, leading to higher discontinuation rates in the experimental ...

Trastuzumab 600mg, hyaluronidase-oysk 10000 ... using FDA-approved tests specific for breast cancer. Embryo-fetal toxicity (eg, oligohydramnios); monitor during pregnancy or within 7 months ...

"It's not only the response rate which is indeed numerically much higher, but it is the lower toxicity of this drug compared to traditional chemotherapies and Herceptin," she added. T-DM1 is the ...

The anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves ... febrile neutropenia, and dry skin were higher by at least 5 percentage points ...

Subcutaneous administration of trastuzumab and pertuzumab significantly ... and shortened the workflow for the pharmacy. “Time toxicity doesn’t get talked about enough,” Adrienne G.

is another type of trastuzumab treatment that is injected underneath the skin. Pertuzumab (Perjeta) treats HER2-positive early breast cancer, usually in combination with trastuzumab and chemotherapy.

Subcutaneous administration of trastuzumab/pertuzumab could save breast cancer patients and healthcare providers substantial amounts of time compared with intravenous ...